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This article presents an overview of factors associ-
ated with thoracic transplantation outcomes over the
past decade and provides valuable information regard-
ing the heart, lung, and heart-lung waiting lists and
thoracic organ transplant recipients. Waiting list and
post-transplant information is used to assess the im-
portance of patient demographics, risk factors, and pri-
mary cardiopulmonary disease on outcomes.
The time that the typical listed patient has been
waiting for a heart, lung, or heart-lung transplant
has markedly increased over the past decade, while
the number of transplants performed has declined
slightly and survival after transplant has plateaued.
Waiting list mortality, however, appears to be declin-
ing for each organ and for most diseases and high-
severity subgroups, perhaps in response to recent
changes in organ allocation algorithms. Based on per-
ceived inequity in organ access and in response to a
mandate from Health Resources and Services Ad-
ministration, the lung transplant community is
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developing a lung allocation system designed to min-
imize deaths on the waiting list while maximizing the
benefit of transplant by incorporating post-transplant
survival and quality of life into the algorithm. Areas
where improved data collection could inform evolving
organ allocation and candidate selection policies are
emphasized.
Key words: Allocation policy, deceased donors, graft
survival, heart transplantation, heart-lung transplanta-
tion, living donors, lung transplantation, organ dona-
tion, patient survival, SRTR, waiting list
Introduction
The intent of this analysis is to present an annual perspec-
tive on the evolution of thoracic transplantation in the USA
and to offer insights that may lead to more efficacious al-
location of donor organs, to be measured as improved net
outcomes for the entire population of patients who might
benefit from a thoracic organ transplant procedure. In addi-
tion to the survival benefit, quality of life and equity should
be considered integral to any net outcome analysis, and,
where relevant data are available, perspectives are pre-
sented on what this information reveals.
Data compiled over the past decade for thoracic organ
transplant patients were analyzed to assess the impor-
tance of patient demographics, risk factors, and primary
cardiopulmonary disease on trends in waiting list time and
mortality. Analysis also sought to identify the character-
istics of thoracic transplant recipients and their associ-
ated post-transplant outcomes. The focus in this report is
on emerging trends either evident from or arguably ob-
scured by the available data. Areas where improved data
collection and analysis could favorably influence heart and
lung transplant outcomes through policy are particularly
emphasized.
Unless otherwise noted, the statistics in this article come
from reference tables in the 2003 OPTN/SRTR Annual
Report. Two companion articles in this report, ‘Trans-
plant data: sources, collection, and caveats’ and ‘Ana-
lytical approaches for transplant research’, explain the
methods of data collection, organization, and analysis that
serve as the basis for this article (1,2). Additional detail
on the methods of analysis may be found in the ref-
erence tables themselves or in the Technical Notes of
the OPTN/SRTR Annual Report, both available online at
http://www.ustransplant.org.
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Heart
Heart waiting list characteristics
Confirming a trend that became evident at the recent turn
of the century, the number of total registrants on the heart
transplant waiting list decreased again in 2002, from 3934
in 2001 to 3803. This number still represents a large in-
crease over the 2798 candidates who were listed at the end
of 1993. Nevertheless, the waiting list growth observed in
the early 1990s seems to have peaked in the USA, as in the
UK (3). The decline in total numbers of registrants has been
associated with a gradual increase in average candidate
age. While the percentage of registrants aged 1–34 years
has remained fairly constant over the past 10 years, the
proportion of potential recipients aged 65 years or older
has increased from 5% in 1993 to 12% in 2002, at the
relative expense of younger adults (Figure 1).
Most waiting list characteristics have not substantially
changed since the last report and reflect the racial charac-
teristics of the US population as a whole (Figure 2). Notably,
the percentage of Hispanic/Latino registrants has grown
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Figure 2. Heart waiting list registrants, by race, 2002.
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Figure 3. Heart waiting list registrants, by median time waiting,
1993–2002.
from 4% at the end of 1993 to 8% in 2002. Although
they are now our most populous minority, relative under-
representation of this ethnic group probably reflects their
comparative youth, although socioeconomic factors may
also contribute. The actual number of female candidates
has stabilized over the past few years, but their total per-
centage has increased as the number of male candidates
has decreased. Adult females with heart failure have less
coronary disease and tend to be older than their male co-
horts, a factor that may contribute to the aging of the over-
all waiting list (4,5). Alternatively, the older average age of
the waiting list may reflect a willingness to list carefully
selected patients over the age of 60 years, because their
outcome has not substantially differed from younger can-
didates after transplant.
In the past 10 years, there has been a marked increase
in the time that the typical patient listed at year-end has
waited for a transplant, as depicted in Figure 3. At the end
of 2002, 48% of candidates had spent more than 2 years
on the waiting list, compared with 17% in 1993. In addi-
tion, 1742 registrants were listed as temporarily inactive at
year-end (about 46% of the entire cohort), up from 37% in
1999. There are a variety of reasons why a candidate may
become inactive, and it is difficult to determine why this
percentage has risen over the years. Whether listing prac-
tice, improvement in medical management, or other fac-
tors are responsible is a question worthy of further inquiry.
It is also clear that some registrants are removed from the
list for reasons other than death or transplant. In 2002, for
example, there were 571 candidates removed from the list
for reasons other than death, transplantation, or transfer,
48% of whom were noted to have improved significantly
and no longer required heart transplantation. Delineation
of reasons for inactive listing and removal from the waiting
list could improve our understanding of this phenomenon
and guide appropriate policy development.
Since 1999, the highest priority candidates have been
sorted into Status 1A and 1B, with the latter listing
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category consistently about three times larger than the for-
mer. Interestingly, the median time to transplant for both
Status 1A and 1B candidates has steadily dropped since
the 1A/1B system was implemented in 1999; the median
time for candidates originally listed at Status 1A decreased
from 145 days in 1999 to 94 days in 2002. Many factors that
are not apparent in this data set—interregional variation in
status at listing or transplant, how this changes over time,
and characteristics that distinguish 1A from 1B patients—
would provide valuable information to assess efficacy and
equity of the evolving allocation paradigm.
Overall, there has been a declining trend to the median
time to transplant for patients over 10 years old (Figure 4).
As has been true for decades, registrants with blood type O
continue to wait much longer than those with other blood
types. Whereas race/ethnicity does not seem to correlate
with differences in waiting time, women had a shorter
median time to transplant than did men (179 vs. 247 days
in 2002). This pattern has persisted over several years and
may reflect relatively greater access of women, who have
lower average weight and height than men, to a larger pro-
portion of donors of either sex.
Over the 10 years of this report, waiting list mortality rates
have declined steadily (Figure 5). There were 143.8 deaths
per 1000 years at risk in 2002, the lowest rate in the last
10 years. This trend in survival improvement was seen in
most age and racial subgroups. Improved medical manage-
ment of heart failure (such as increasing use of implanted
cardiac defibrillators) to prevent sudden death in wait-listed
patients, more optimal timing of listing for transplant, and
the altered organ allocation policy implemented in 1999 all
probably contributed to this favorable trend. It is also pos-
sible, however, that transplant teams removed candidates
from the active list when death was imminent, artificially
reducing program-specific and overall waiting list mortal-
ity. Although the total number of candidates initially listed
as Status 1A has steadily increased from 1999 to the end
of 2002, the death rate for this critically ill group has also
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Source: 2003 OPTN/SRTR Annual Report, Table 11.3.
Figure 5. Annual death rates for heart transplant registrants by
age, 1993–2002.
1999 to 785 in 2002. Candidates with blood type AB appear
to have benefited the least, in that waiting list mortality for
this relatively small group (17 of 558 deaths among 6990
listed patients in 2002) has not fallen.
In summary, despite great advances in the detection, pre-
vention, and management of heart failure, there continue
to be more candidates for heart transplant than there are
available donor organs deemed suitable for use (6–8). Af-
ter being placed on the waiting list, patients face one of
three competing outcomes: transplantation, death on the
waiting list, or removal from the waiting list. The relative
rate of heart transplant has remained level and death on
the waiting list has apparently decreased, therefore one is
forced to conclude that the rate of removal from the wait-
ing list has increased correspondingly. The fate of these
patients is not currently accessible, thus the significance
of this observation is uncertain. This limitation to continued
candidate listing appears to have forestalled the impending
crisis predicted for cardiac transplantation in 1994 (9). If we
were to learn that the decrease in waiting list mortality rate
is an artifact of program policies rather than more timely
access to life-saving organs for a shrinking population in
need, the implications for organ allocation policy would be
fundamentally altered.
Heart transplant recipient characteristics
After rising steadily during the 1980s and early 1990s,
the total number of heart transplants performed has de-
clined by about 8% over the last 5 years, from a mid-1990s
plateau of about 2350 to about 2150 per year over the past
4 years (Figure 6). Although patients between the ages of
35 and 64 years continue to receive the majority of donated
hearts (67%), the proportion of all recipients in this group
has declined by about 9% since 1993, as the number of
recipients over 65 has increased from 5% to 10% of those
transplanted. Women now constitute 28% of recipients,
up from 22% a decade ago. The relative rate of transplan-
tation per million population has declined for men to 2.7
from 3.8 in 1993 (Figure 7). These data may reflect the in-
creasing incidence of end-stage heart failure in women and
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Source: 2003 OPTN/SRTR Annual Report, Table 11.5. 
Figure 7. Incidence rate of heart transplant male relative to fe-
male, 1993–2002.
the persistent influence of a younger average age at onset
in men. Racial and ethnic breakdowns are similar over the
past 5 years, except that the recent trend towards an in-
creasing proportion of Hispanic/Latino recipients appears
to have stabilized at about 8% of all heart recipients, in
concert with their relative representation on the waiting
list.
From 1999 to 2002, the distribution of patient status at
transplant remained stable; about 38% of patients trans-
planted were classified at Status 1A, 36% at Status 1B,
and 26% at Status 2. Sixty-five percent of heart recipients
were on life support (principally inotrope infusion or ven-
tricular assist devices, or VAD) at the time of transplant in
2002, unchanged for the most part since 1995. The per-
centage of recipients who were hospitalized at the time
of transplant has declined from a high of 68% in 1997 to
53% in 2002. Similarly, the percentage of those in the in-
tensive care unit at the time of transplant has dropped from
59% in 1997 to 34% in 2002. These trends are an intended
consequence of the policy change implemented in 1999,
when patient location (in or out of hospital) was removed
from the allocation algorithm as a dominant factor. No ad-
verse impact on waiting list or post-transplant mortality is
evident in the available data, although the uncertain fate of
patients removed from the waiting list (discussed above)
lends some uncertainty to this apparently favorable trend.
The consequences of this policy change and associated
trends on costs, quality of life, physician practices, and pa-
tient safety while waiting would be fruitful areas for study,
to identify opportunities for further policy improvement.
Coronary artery disease and cardiomyopathy continue to
be the primary diagnoses associated with heart transplant,
as they are with listing, and are represented in similar pro-
portions (approximately 45% each) over the past 10 years.
Congenital heart disease accounts for about 8%, and re-
transplantation, most often for primary graft failure or car-
diac allograft vasculopathy, remains uncommon, account-
ing for about 3% of both listings and transplants in recent
years.
Unadjusted heart recipient survival at 1 year has risen
slowly, from 81% for patients transplanted in 1992 to
86% in 2001, and at 5 years exceeds 70% for the co-
hort of patients transplanted in 1996–1997. Graft survival
is only slightly lower, as expected for an organ where near-
term survival is critically dependent on initial function of a
scarce graft and where mechanical circulatory support in
the event of initial graft failure is highly morbid. Survival
trends evaluated by race, ethnicity, gender, blood type,
life support requirement, and location (in or out of hospi-
tal) did not change appreciably relative to the 2002 report.
Among all demographic parameters, a history of prior heart
transplant and African-American race portended the worst
5-year graft survival when compared with primary trans-
plant and other racial categories, respectively. Efforts to
prevent graft failure, attenuate the physiologic burden of
chronic immunosuppression, and understand how racial
differences interact with survival may lead to improved out-
comes for these important patient subgroups and, thus, to
incremental improvement in overall outcomes.
One-year graft survival by primary diagnosis remains simi-
lar for cardiomyopathy (88%) and coronary artery disease
(85%); 5-year graft survival rates were highest for valvular
heart disease (76%) and cardiomyopathy (72%). After re-
maining very constant for 6 years, the overall death rate
within the first year after transplant fell in 2002, from 161–
179 to 121 per 1000 patient years at risk. While incomplete
follow-up for patients transplanted in the most recent year
probably overestimates the actual increase in patient sur-
vival, the death rate within the first year for patients trans-
planted in each category of urgency (1A, 1B, 2) at the time
of transplant appears to be declining. Survival at 1 year is
similar for Status 1B and Status 2 (88%), and is lower for
Status 1A (81%), with the difference appearing within the
first 3 months. Early mortality is thus probably explained
by known risk factors that qualify patients for the 1A cat-
egory, including pathophysiologic events complicating the
initial transplant episode in patients who are unstable be-
fore transplant, such as those with infected VADs or requir-
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ing mechanical ventilation. Logically, better approaches to
manage patients on life support could reduce this early
attrition, while identification of low-risk windows of oppor-
tunity within which to perform the transplant after invasive
or intensive support measures could justify policy changes
designed to take advantage of this information.
Survival data are not currently collected separately for tech-
nical variations (bicaval right atrial or total atrioventricular
vs. conventional biatrial cuff) on the prevalent orthotopic
surgical approach. While heterotopic (‘piggy-back’) heart
transplantation is rare (4–21 per year in the USA since
1993), patient survival for this procedure is decreased at
1 year (82%) and 5 years (35%) compared with orthotopic
transplantation (86% and 72%, respectively). Early mortal-
ity is surprisingly low despite selection of high-risk patients
(typically those with fixed elevation of pulmonary vascu-
lar resistance) to undergo this uncommon and technically
demanding procedure. If causes of adverse late outcome
were known and could be addressed, it is conceivable that
this technique could allow safer use of expanded criteria
donor hearts without adversely influencing recipient out-
come.
Donor age remains a significant risk factor for adverse
intermediate-term outcome. Heart transplant numbers and
rates are declining despite a significant increase in av-
erage organ donor age and in heart donor age over the
past decade, while demographics suggest that demand
for hearts should increasingly outstrip supply. Considered
together, these facts suggest that heart transplant teams
may be reluctant to use older organs. Efforts to under-
stand the causes of increased risk with increasing heart
donor age will be important to identify solutions and thus
justify increased use of these organs. In particular, better
prediction of who is likely to benefit from receipt of an
older donor heart would be valuable. These imperatives
will be tempered if results using long-term mechanical
circulatory support devices improve to equal those with
transplantation.
When analyzed by recipient age, intermediate term sur-
vival data show that the very young (those less than 1
year old, about 70 per year) and patients between 50 and
64 years of age (about 1100 per year) have relatively low
mortality after the first year (about 14% additional attri-
tion by year 5), compared with approximately 18% inter-
mediate term mortality for patients aged 1–50 years and
those over 65 years (estimated based on data in Table
11.11, OPTN/SRTR 2003 Annual Report). This observation
indirectly supports the hypothesis that either immature or
senescent immunity facilitates relatively good long-term
outcome. Higher intermediate-term mortality among those
patients over 65 years of age who are deemed suitable can-
didates probably reflects the expected influence of rising
all-cause mortality with increasing age in this age range.
Data from the Registry of the International Society for
Heart and Lung Transplantation (ISHLT) provides longitudi-
nal information on more than 59 000 cardiac transplants
world-wide (10,11). Actuarial survival over the past two
decades shows a patient half-life of 9.3 years with a condi-
tional half-life of 12 years among those surviving to hos-
pital discharge. Risk factors for both early (1 year) and
intermediate-term (5 year) mortality in adult cardiac trans-
plantation includes preoperative ventilator dependence,
prior cardiac transplantation, congenital heart disease as
the indication, increasing recipient and donor age, and in-
creasing donor ischemia time. In the cohort transplanted
since the beginning of 1999, the need for dialysis, increas-
ing recipient age (over 50 years), residence in an ICU at
the time of transplant, and low center volume appear to be
increasingly important risk factors for 1-year mortality, rel-
ative to patients transplanted in 1995–1998. At 1-year
follow-up, the majority of deaths are attributed to infection
and acute rejection. By 5 years, cardiac allograft vascu-
lopathy (chronic rejection), malignancy, and graft failure of
unspecified or unknown etiology are the principle causes
of mortality.
Our clinical impression is that the current data set may
underestimate a major demographic shift in the patient
population coming to heart transplant. Young patients with
idiopathic dilated cardiomyopathy come to transplant less
frequently, perhaps as a consequence of better medical
management. Increasingly, elective referrals are of older
diabetic patients with coronary artery disease. The typical
patient requiring a VAD has changed from the slowly dete-
riorating listed patient with idiopathic disease to the acute
myocardial infarction patient with hemodynamic instability
presenting for emergent support, and whose evaluation
of necessity can only occur subsequent to device implant
and stabilization. We expect this clinical impression will be-
come more evident in future analyses.
Lung
Lung waiting list characteristics
The lung waiting list has continued to expand during the
past year, reaching a new record high of 3756 registrants
as of December 31, 2002. This growth reflects a small in-
crease over 2001 and an increase of over 300% since 1992.
Over the past 5 years (1998–2002), however, the number
of active patients at year-end has stabilized between about
2300 and 2500, while the percentage of active registrants
has continued to decline. The number of new registrations
also dropped slightly to 1892, the lowest number since
1996.
A trend towards increased numbers of patients with in-
active status on a waiting list snapshot, as seen in Fig-
ure 8, partially accounts for the observed increase in the
total number of registrants on the lung waiting list, with
a 15% increase among inactive patients since 2001 and a
more than threefold increase since 1995. Although a re-
versible deterioration in patient status may, on occasion,
transiently prohibit transplantation, it is likely that this trend
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reflects an increasingly common practice of early place-
ment on the waiting list. End-stage lung patients are ac-
tively listed relatively early in the course of their disease
in order to accrue waiting time in the likely eventuality of
subsequent deterioration. Under current allocation guide-
lines, remaining inactive on the waiting list (rather than be-
ing removed from the list) allows previously accrued active
time to be retained. This approach gives the individual pa-
tient with relatively stable and predictable disease a bet-
ter chance of getting an organ, because waiting list time
is the most influential single determinant of organ prior-
ity (assuming geographical proximity and blood type com-
patibility). As such patients begin to receive organ offers,
they are inactivated until the transplant team judges that
they are ill enough to benefit from acceptance of an or-
gan. This practice of early placement on the waiting list, al-
though advantageous on a patient-by-patient basis, is not
necessarily in the best interest of the larger community
of wait-listed lung patients, because, frequently, patients
in need of transplantation do not have the opportunity to
be wait-listed early in the course of their disease. Future
allocation plans will probably (and appropriately) involve
more parameters that reflect medical urgency and, per-
haps, probable utility, while de-emphasizing time waited
after listing, as discussed in the final section of this
article.
Compared with 10 years ago, a higher percentage of lung
waiting list registrants are older than 50 years, increasing
from 38% in 1993 to 50% in 2002 (Figure 9). The percent-
age of African-American and Hispanic/Latino registrants on
the lung waiting list increased from 6% and 2%, respec-
tively, in 1993 to 11% and 5%, respectively, in 2002. Wait-
ing list registrants were most commonly female (58%),
older than 50 years of age (50%), white (87%), blood type
O (49%), US residents (99%), and awaiting their first trans-
plant (97%). Approximately 65% of registrants have been
waiting more than a year for an available organ, and 42%
of all listed patients waited for more than 2 years (these
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Source: 2003 OPTN/SRTR Annual Report,Table 12.1. 
Figure 9. Age distribution of lung waiting list at year-end, 1993–
2002.
waiting times include periods of inactive waiting list sta-
tus). Even with the current allocation of 90 days of bonus
waiting time for idiopathic pulmonary fibrosis (IPF) patients,
these wait time statistics are daunting in the context of this
unpredictable and often rapidly progressive disease.
Although observed quartiles of time to transplant showed
a tendency to increase between 1993 and 1999, more re-
cent data suggest a reversal of this trend. As shown in
Figure 10, 25% of recipients in 1999 were transplanted
within 451 days of listing, whereas in 2002, this same per-
centage of recipients was transplanted within 251 days of
listing, a 41% reduction to a level also seen in 1993 and
1996. Counterbalancing the general trend towards longer
average times to transplant were decreasing annual death
rates on the waiting list (Figure 11), which decreased from
236 deaths per 1000 patient years at risk in 1993 to a
10-year low of 131 in 2002. This trend is probably a re-
sult, at least in part, of improving care for end-stage lung
patients over time. However, it may also reflect the, on av-
erage, healthier patient years at risk contributed by patients

















Source: 2003 OPTN/SRTR Annual Report, Table 12.2. 
Figure 10. Twenty-fifth percentile time to transplant of new lung
waiting list registrants, 1993–2002.


































Source: 2003 OPTN/SRTR Annual Report, Table 12.3. 
Figure 11. Annual death rates per 1000 patient years at risk on
the lung waiting list, 1993–2002.
calculating the death rate. Hence, the change in average
waiting list mortality over time should be interpreted cau-
tiously. That is, these trends simultaneously reflect the
overlapping influences of the wider acceptance of trans-
plant for end-stage lung disease, the concomitant recogni-
tion of the need for accumulated wait time to enable ac-
cess to this life-saving therapy for individual patients, and
the resulting change in the typical wait-listed patient on the
waiting list. As individuals attempt to adjust to the current
allocation system in anticipation of their own needs, it is
likely that some of the patients most in need of transplant
are being increasingly disadvantaged by the current alloca-
tion rules.
For patients listed in 2002, relatively favorable times
to transplant were observed for candidates older than
50 years, with 25% of recipients aged 50–64 years trans-
planted within 222 days and 25% of recipients over
65 years of age being transplanted within 100 days in 2002.
In contrast, over 75% of patients aged 11–17 years, 18–
34 years, and 35–49 years waited for more than 421 days,
399 days, and 336 days, respectively, to be transplanted.
Greater flexibility in organ acceptance criteria may be con-
tributing to the shorter times to transplant in older waiting
list patients. Annual death rates per 1000 patient years on
the lung waiting list in 2002 were relatively low for patients
aged 11–17 years (148), 18–34 years (138), 35–49 years
(111), and 50–64 years (132), respectively. The 1–5 year
age group had the highest annual death rate while waiting
(238 deaths per 1000 patient years).
Perhaps because there have been consistently between
10% and 20% more women than men on the waiting list
over the past decade, the observed time to transplant has
tended to be longer for women than for men. Interest-
ingly, despite the longer average wait time for women, in
most years annual death rates per 1000 patient years at
risk on the waiting list were slightly higher for men than
for women. For example, in 2002 men experienced 147
deaths per 1000 patient years at risk vs. a death rate of
119 among women. The explanation for these apparently
discordant statistics is obscure, but, speculatively, may re-
flect earlier onset of pulmonary symptoms but relatively re-
duced physiologic consequences in patients with smaller
body size or a different hormonal environment.
Potential approaches for increasing the average years of
life saved per organ via risk-based waiting list prioritizations
are growing in popularity (see below, Current Proposal for
Deceased Donor Lung Allocation Policy in the USA). Re-
vised listing and allocation criteria may eventually reduce
the perceived imperative to place candidates on the wait-
ing list at early disease stages. The OPTN/UNOS Thoracic
Committee is currently investigating allocation algorithms
for this purpose, with the objective of creating priority on
the waiting list by balancing risk of death on the waiting list
vs. post-transplant outcome (12).
Lung transplant recipient characteristics
Over the last 10 years, the total number of lung transplants
has slowly increased from 667 transplants performed in
1993 to 1054 in 2001. In 2002, the total number decreased,
to 1041; this is the third time in the past 10 years that there
has been a slight decline in volume in comparison with the
previous year. This plateau in the number of recipients is
most likely because of both the relatively small increase
in the total number of lung donors combined and the in-
creasing number of double (vs. single) lung transplants
performed (discussed below). Patients in their fourth, fifth,
and sixth decades of life account for the majority of trans-
plant recipients, with the largest cohort, those 50–64 years
old, representing nearly 56%. Racial breakdowns have re-
mained unchanged, with the great majority (>90%) of re-
cipients characterized as white. Gender distribution over
the years has varied slightly, with an approximately equal
distribution between male and female recipients. Given the
higher proportion of women on the waiting list, it is unclear
why such a discrepancy exists. A possible explanation is
smaller recipient size, with fewer small donors and a reluc-
tance to oversize. Other factors may relate to differences
in gender distribution within each of the pretransplant di-
agnoses combined with the differences in the waiting time
for those diagnoses and improvements in medical care.
The major primary diagnoses and percentages for the 2002
cohort were as follows: emphysema (39%), IPF (19%),
cystic fibrosis (16%), alpha-1-antitrypsin deficiency (8%),
and primary pulmonary hypertension (PPH, 5%). The per-
centage of transplants for emphysema decreased, while
the other diagnostic groups had commensurate small in-
creases since 2001 (Figure 12). Furthermore, 98% of lung
recipients had not undergone any previous solid organ
transplant. The majority of recipients were not hospital-
ized at the time of transplantation, and less than 6% of
patients were on life support when transplanted. Recipi-
ents in the intensive care unit immediately prior to trans-
plant had significantly lower graft survival rates at all time
points compared with the hospitalized or nonhospitalized
cohorts. In comparison with 1993 and 1994, when more
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Figure 13. Deceased donor lung transplant recipients, by proce-
dure, 1993–2002.
than 60% of lung transplant procedures involved single
lung transplantation, the period from 1995 through 2001
shows an increasing use of double lung transplantation,
with the data from 2002 showing, for the first time, dou-
ble lung transplantation exceeding single lung procedures
(Figure 13). Whether this trend reflects an increasing ac-
ceptance of double lung transplantation as a preferen-
tial procedure for recipients with diagnoses that have
previously been treated with single lung transplantation
remains to be seen. While there have been retrospec-
tive analyses showing an improved intermediate and
long-term survival for double lung recipients, these com-
parisons have not been adjusted for potentially signifi-
cant confounding variables, such as age and underlying
diagnosis.
One-year adjusted graft survival was 77% (for the 2001
cohort) and has been essentially unchanged over the past
9 years (75% graft survival in 1993) (Figure 14). With the
very low incidence of retransplantation (2% of all recip-



















Source: 2003 OPTN/SRTR Annual Report, Table 1.12a.
Figure 14. One-year adjusted lung graft survival, 1992–2001.
than graft survival. One- and 5-year patient survivals were
78% and 45%, respectively. Adjusted graft survival was
77% at 1 year (2000–2001 cohort) and 44% at 5 years
(1996–1997 cohort). The 11–17 year old group had the low-
est 3-month graft survival at 82%, and this same group
(along with the 6–10 year olds) had the worst 5-year graft
survival at only 23%. The best 5-year graft survival, al-
beit still only 50%, was seen among those aged 35–49
years. By race, 5-year graft survival was lowest in African-
Americans at 30%, whereas whites had a higher 5-year
survival rate of 45%. Ethnicity, gender, and blood type did
not have a notable independent effect on short- or long-
term graft survival. Of all demographics, a history of prior
lung transplant portended the worst 1-year (53%), 3-year
(30%), and 5-year (35%) graft survival. This is in keep-
ing with other published reports, such as the 2003 ISHLT
registry report (13), which shows a significantly increased
risk of 1-year mortality in this group, with an odds ratio
of 2.03. Interestingly, those data reveal that the increased
mortality is only significant for the first year, and not at
5 years. Graft survival in relationship to the primary di-
agnosis leading to transplant was highest at all periods
during the first 3 years for emphysema/chronic obstruc-
tive pulmonary disease, followed by cystic fibrosis. The
diagnosis with the highest 5-year graft survival rate was
alpha-1-antitrypsin deficiency (46%)—aside from the 212
patients with a diagnosis of ‘other’ (50%). These were fol-
lowed by emphysema/chronic obstructive pulmonary dis-
ease (45%). Retransplantation, congenital (heart) disease,
and PPH had the lowest 5-year graft survival rates at 35%,
32%, and 28%, respectively (Figure 15).
While the number of recipients of living donor lungs is in-
sufficient for statistical comparisons with recipients of de-
ceased donor lungs, there are some interesting differences
between the two groups. The vast majority of the living
donor lung recipients are in the 11–17 year and 18–34 year
age ranges, consistent with the high percentage of these
recipients having cystic fibrosis. The next largest diagnos-
tic indication is retransplantation. The majority of this group
was hospitalized prior to the transplant: in 2002, 39% were


























Emphysema/COPD CF IPF A1A PPH
Source: 2003 OPTN/SRTR Annual Report,Table 12.8a. Cohorts 
are for transplants performed during 2000-2001 for 3 month & 1 year;
1998–1999 for 3 year; and 1996-1997 for 5 year survival.
Figure 15. Adjusted graft survival among deceased donor lung
transplant recipients by diagnosis.
in the hospital and an additional 15% were in the intensive
care unit prior to the transplant. Interestingly, adjusted pa-
tient survival was 73% (vs. 78% for the deceased donor
group) at 1 year and 50% (vs. 45%) at 5 years The low-
est unadjusted 5-year patient survival rates were seen in
those recipients in the intensive care unit preoperatively
(25%) and in those recipients on preoperative life support
(17%).
Data from the ISHLT registry provides information on more
than 12 000 adult lung transplants world-wide (13). Actuar-
ial survival over the past decade shows a patient half-life of
4.1 years with a conditional half-life of 6.6 years. Major risk
factors for 1-year mortality include pretransplantation diag-
nosis (PPH > sarcoidosis > idiopathic pulmonary fibrosis >
all other diagnoses), preoperative ventilator dependence,
preoperative intravenous inotropes, and prior lung trans-
plantation. Increasing recipient and donor age, increasing
organ ischemia time, and decreased center volume (cases
per year) were also significant risk factors. Continuous vari-
ables that significantly affected 5-year mortality included
increasing recipient age beyond 50 years and increasing
donor age beyond 30 years.
Lung transplantation is now widely accepted as a viable
treatment for a heterogeneous group of end-stage lung
diseases, with an associated expansion in the number of
potential transplant candidates. Although recent interna-
tional guidelines have been developed for determining can-
didacy, the listing decisions are still highly influenced by
individual patient considerations. Listing policy, however,
is difficult to codify because of varied pathogenesis and
often unpredictable natural histories. As mentioned previ-
ously, the current system exerts pressure to place patients
on the waiting list at earlier stages of lung disease in re-
sponse to longer average times to organ availability, as has
been commented on recently in the context of cystic fi-
brosis, pulmonary fibrosis, and sarcoidosis (14–18). These
trends toward earlier diagnosis and more broadly defined
criteria for adding patients to the waiting list are not with-
out potential consequences. In describing 5-year survival
rates for wait-listed cystic fibrosis patients, Liou et al. re-
cently argued that an increase in the number of patients
with long survival rates on the waiting list has a deleteri-
ous effect on survival for patients with poorer short-term
prognosis at diagnosis, who find themselves at a competi-
tive disadvantage (19). The increasing numbers of patients
with apparently better prognoses appearing on the waiting
list, not to mention improvements in patient care, may have
overwhelmed this effect and resulted in the observed de-
crease in the average waiting list mortality rate. The critical
shortage of donor lungs remains painfully evident to pa-
tients and clinicians. With respect to policy, the key ques-
tion may be whether utilization of a scarce resource (lungs)
is being optimized for efficacy (net years of life saved for
the end-stage lung failure population, improved net qual-
ity of life for those transplanted) or equity (fair access, and
improved access for patients at greatest risk of death while
waiting).
Heart-Lung
Heart-lung waiting list characteristics
The total number of registrants awaiting heart-lung trans-
plant fell below 200 in 2002, and in that year only 88 new
patients were listed. Among listed patients, 54% were on
the active waiting list. Median time to transplant cannot
be calculated for heart-lung candidates listed since 1993,
because more than 50% of the patients listed each year
have yet to be transplanted. Although the 25th percentile
for time to transplant declined from a high of over 700 days
for patients listed in 1997 to just under 400 days for patients
listed in 1999, for patients listed in the past 3 years it con-
tinues to hover between 1 and 2 years. The average age
and proportion of minority registrants increased over the
past 10 years. The waiting list death rate declined slightly,
to 186 per 1000 years at risk, still among the highest for any
group of transplant patients. Although the absolute num-
ber of deaths is relatively small (38 in 2002), it continues to
exceed the annual number of transplants performed. Thus,
only a minority of heart-lung registrants actually received a
transplant and most candidates waited more than 2 years.
Further changes in the allocation of heart/lung are being
considered by the OPTN/UNOS Thoracic Committee.
Heart-lung transplant recipient characteristics
Only 32 heart-lung transplants were reported in 2002, up
slightly from 27 in the previous year. Common indications
are congenital heart disease (31%, primarily Eisenmenger
Syndrome), and PPH with irreversible heart failure (38%).
Potential heart-lung candidates often do not receive organs
until they are listed as Status 1A on the heart waiting list
(47% hospitalized, 50% on life support).
The annual death rate following heart-lung transplanta-
tion remains high compared with other organs, but it has
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dropped consistently since peaking in 1997, and in 2002
was only 171 per 1000 patient years at risk, down sharply
from 432 in 2001. Actuarial graft and patient survival at
3 months and 1 year lags behind that for double lung
transplantation. This early survival disadvantage is prob-
ably related to the technical challenges of controlling the
bleeding associated with scarring from prior surgery or in-
flammation, complex anatomy, prolific vascular collaterals
common in these patients, and liver congestion from right
heart failure.
Long-term outcome after heart-lung transplantation is sim-
ilar to that for double lung transplantation, with adjusted
5-year survival at about 40%. Only four centers performed
more than two heart-lung transplants in 2002; only 18 pro-
grams have performed 10 or more since 1993, and only
Stanford, with 85 over the past decade, has averaged more
than eight per year. Organ allocation policy should continue
to consider the needs of this small group of young, chal-
lenging patients who rarely have other good options.
Current Proposal for Deceased Donor Lung
Allocation Policy in the USA
The current algorithm for lung distribution in the USA was
introduced in June 1990 and was modeled after the dis-
tribution system for hearts. Lungs are offered first to re-
cipients within the OPO where the donor is hospitalized
based on active waiting time, and, if not allocated locally,
the lungs are then offered to appropriate ABO identical
or compatible recipients listed at transplant centers within
concentric 500 nautical mile circles. In March 1995, the al-
gorithm was modified to assign 90 days of waiting time at
listing to patients with IPF in response to the perception
that these patients were deteriorating more rapidly than
other patients and dying before organs were being made
available to them.
The 1999 Final Rule for operation of the OPTN included
a requirement to examine organ distribution algorithms to
minimize the impact of geography on prospects for trans-
plantation. The mandate for the OPTN is to achieve the best
use of organs by directing organs to those most in need,
while at the same time maximizing utility of organs by not
wasting them on futile transplantation of individuals likely
to be too sick to survive the operation or derive an impor-
tant quality of life benefit (20). In addition, the Final Rule
required that the OPTN Board of Directors develop poli-
cies for organ allocation that are based on sound medical
judgment and that seek to achieve the best use of organs.
Although the initial debate focused on liver distribution, the
Final Rule required the OPTN to examine all organ distribu-
tion algorithms and either demonstrate that they satisfied
the principles espoused or alter the algorithms to address
the new philosophy.
The OPTN/UNOS Thoracic Organ Committee established
a subcommittee to study the lung distribution algorithm
and make recommendations to comply with the Final Rule.
Members of the Lung Allocation Subcommittee concluded
that the current system was flawed. One effect of alloca-
tion based on waiting time was the growing practice of
listing patients before they truly needed to be transplanted
(21). A second consequence was the observation that pro-
portionately fewer patients with chronic obstructive pul-
monary disease (COPD) were dying on the list compared
with those with IPF and cystic fibrosis. Presumably, those
who could survive the longest on the waiting list had a bet-
ter chance of being offered a lung or lungs for transplant,
even though there appears to be no survival benefit of lung
transplant for the large number of patients with COPD un-
dergoing the procedure (22).
The subcommittee believed that an ideal allocation system
would minimize deaths on the waiting list, while at the
same time maximize the benefit of transplant by incorpo-
rating post-transplant survival into the algorithm. Several
analyses were performed to determine the feasibility of
designing such an algorithm. First, patients added to the
lung transplant waiting list between January 1, 1997 and
December 31, 1998 with the four most common diagnoses
were analyzed to determine if data submitted at the time
of listing could predict death on the waiting list. Over 3100
patients with COPD or alpha-1-antitrypsin deficiency em-
physema (n = 1461), cystic fibrosis (n = 708), IPF (n =
608), or PPH (n = 327) were included in the analysis. A
logistic regression model was fitted for each of the four
diagnoses using death on the waiting list as the outcome.
Over 30 clinical and demographic variables collected at the
time of listing were included in the models. Patients were
censored at the time of transplant. A number of factors
were identified for each diagnosis that were associated
with a significantly increased risk of death on the waiting
list (23,24).
To establish if any of these risk factors could predict death
after lung transplant, another analysis was performed on
patients with the same four diagnoses. Patients undergo-
ing lung transplant between January 1, 1996 and June 30,
1999 (n = 2484) were analyzed to establish if data col-
lected at the time of listing could predict survival proba-
bility 1 year after transplant. There was a significant effect
of diagnosis on 1-year survival: COPD/emphysema 79.7%,
cystic fibrosis 80.2%, IPF 66%, and PPH 64% (p < 0.0001,
log rank). For each diagnosis, additional factors were identi-
fied that were associated with a significantly increased risk
of death following lung transplant. One-year survival was
chosen for this analysis based on the premise that the pre-
transplant factors that played a role in post-transplant sur-
vival would have a diminishing effect as time went on after
transplant.
Although these analyses were useful, they were limited to
adult patients with the four most common diagnoses and
thus represented approximately 80% of patients listed or
transplanted. The impact of diagnosis was so strong that
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the subcommittee chose to establish whether all patients
listed could be assigned to a diagnostic group for purposes
of identifying risk factors that might be useful to construct
a distribution algorithm.
Analysis of distribution of diagnoses, waiting list survival
probabilities, and post-transplant survival by age for pa-
tients under the age of 18 years, suggested that there
was a break point at age 12. Adolescent and teenage
lung transplant recipients aged 12 and older had similar
diagnoses and survival (waiting list and post-transplant) as
young adults, while children younger than 12 years had dif-
ferent diagnoses and survival probabilities. Thus, the sub-
committee decided to place all potential recipients under
the age of 12 in the pediatric group and all patients 12 and
older in the adult group. Analysis of waiting list and post-
transplant 1-year survival for other end-stage lung disease
diagnoses, along with consideration of pathophysiology,
led to the creation of four diagnostic groups for patients
aged 12 years and older (25).
Patients were grouped as follows for additional analyses
(Table 1). Group A is composed primarily of patients with
obstructive lung diseases and includes sarcoidosis patients
with mean PA pressure <30 mmHg. Group B is composed
of patients with pulmonary vascular diseases. Group C is
dominated by patients with cystic fibrosis, and Group D
is composed primarily of patients with restrictive lung dis-
eases. The prognosis for patients with sarcoidosis corre-
lated with PA (pulmonary artery) pressure: those patients
with a mean PA pressure <30 mmHg had survival simi-
lar to patients with COPD, whereas sarcoidosis patients
with mean PA pressure >30 mmHg had survival similar
to patients with IPF, and were thus considered in those
Table 1. Survival-based diagnosis groupings for lung allocation
modeling
Group A (predominantly obstructive)
COPD, emphysema, chronic bronchitis
Alpha-one antitrypsin deficiency emphysema
Bronchiectasis
Lymphangioleiomyomatosis (LAM)
Sarcoidosis with mean PA pressure ≤30 mmHg
Group B (predominantly pulmonary vascular disease)




Cystic fibrosis, immunoglobulin deficiency, fibrocavitary
lung disease
Group D (predominantly restrictive)
Pulmonary fibrosis, including IPF, occupational lung disease
Collagen vascular diseases
Bronchoalveolar carcinoma




All patients < age 12, regardless of diagnosis
groups. Group E consists of all patients under the age of 12
years, irrespective of the diagnosis of their end-stage lung
disease.
Analyses were repeated for all patients listed between
January 1, 1997 and December 31, 1998. Because of
the relatively small number of patients with pulmonary
vascular disease, data were collected for Group B pa-
tients from January 1, 1995 to December 31, 1998. Group-
specific Cox regression models were used to predict
death on the waiting list. Cox models, rather than lo-
gistic regression, were selected to explore survival rates
at more than one time point. Patients were censored
at the time of transplant. Statistically significant factors
were identified for Groups A–D that were similar to the
earlier analysis, and hazard ratios were calculated for
these factors (26). The number of patients in Group E
(n = 131) and the small number of waiting list deaths
(n = 43) made interpretation of the data for this group
unreliable.
A subsequent analysis of all patients transplanted in the
same timeframe was performed to establish whether data
at the time of listing or transplant could identify factors as-
sociated with survival following transplant. Group-specific
Cox regression models were fitted with post-transplant
death as the outcome to identify these factors and associ-
ated hazard ratios (27).
A number of factors identified as statistically significant
were judged by the Lung Allocation Subcommittee to be
inappropriate to put into an organ distribution algorithm be-
cause they were too subjective to be applied consistently.
An example is being on 5 mg of more of prednisone daily for
Group A patients, which was associated with an increased
risk of death on the waiting list. These factors were elim-
inated from the models but had little effect on the other
variables that were judged appropriate for inclusion in the
algorithm.
Based on individual patient risk factors and associated haz-
ard ratios, the subcommittee then considered options for
summarizing a patient’s risk of death on the waiting list
over the subsequent year as opposed to the patient’s risk
of death during this same period if transplanted. One-year
survival estimates provided by the Cox models were con-
sidered, as well as estimates of the length of time each
patient would live during the next year with or without
transplant. This latter type of summary measure, often re-
ferred to as a 1-year expected lifetime, is calculated for
each individual at the time a donor organ is being consid-
ered by summing up the area under the patient’s 1-year
Cox model estimated survival curve. The subcommittee
selected these 1-year expected lifetime summary mea-
sures to describe each patient’s anticipated waiting list and
post-transplant prognosis after noting that these measures
captured more information about the patient survival pro-
files over time than a 1-year survival rate. Each patient’s
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1-year survival benefit with transplant (measured in days
of life saved with transplant) was then calculated by look-
ing at the difference between the days of life a patient
would be expected to live over the next year if trans-
planted minus the days of life a patient would be expected
to live if maintained on the waiting list over the coming
year (28).
Allocation scores based on the days of life saved within
the first year if transplanted (benefit), days of life expected
during the subsequent year if maintained on the waiting list
(urgency), and combinations of transplant benefit/urgency
were presented to members of the pulmonary medicine
and transplant communities at large at a Lung Allocation
Consensus Conference held in March 2003. Feedback was
obtained for further consideration by the Lung Allocation
Subcommittee.
It is anticipated that serial clinical data will be useful to iden-
tify new factors that should be incorporated into the dis-
tribution algorithm and that serially collected patient data
may affect the import of factors identified as significant in
the analyses. Indeed, it is the recommendation of the Lung
Allocation Subcommittee that analyses be undertaken to
identify factors and modify their hazard ratios in the algo-
rithm at least every 6 months. Thus, as patients are trans-
planted and removed from the list and new patients are
added, risk is assessed using the most recent cohort of
patients.
One shortcoming of the planned change to the algorithm is
that hazard ratios were identified for a cohort of historical
patients, and data were collected at only one or at most
two points in time (post-transplant survival factors were
available at listing or at transplant). To address this issue,
the OPTN is undertaking an analysis of a cohort of recently
listed patients at a large number of centers to determine
if the risk factors and their calculated hazard ratios are ap-
propriate and can justify altering the existing algorithm. It
is anticipated that this approach to lung distribution will
reduce deaths on the waiting list and improve survival fol-
lowing lung transplant.
Summary
Important trends over the past decade are documented for
heart, lung, and heart-lung waiting lists and for correspond-
ing organ transplant recipients. Wait-listed candidates and
thoracic organ recipients include increasing percentages of
older age groups. In general, median time to transplant is
declining and post-transplant survival rates have gradually
improved over the last decade for all thoracic organs. It is
important to note that the large decrease in mortality rate,
apparent for all thoracic organ transplant recipients during
2002 (39% for heart, 66% for heart-lung, 14% for lung re-
cipients), appears to be an artifact of the data collection
process. Similar findings were reported last year for the
2001 results but are not confirmed in this year’s report for
the same 2001 calendar year interval. We conclude that
the most recent year’s data will not be a valuable source
for policy-making unless collection procedures can be im-
proved. The most likely source of this apparent problem is
delayed submission of patient follow-up data to the OPTN.
Nonetheless, gradual improvement in patient access and in
short- and long-term survival appear to be sustained for all
thoracic organs and in most patient demographic groups,
suggesting favorable influences of recently implemented
policies and continued improvement in patient selection
and management. Improved information will permit op-
timal use of these precious organs according to criteria
that are generally agreed upon (and, increasingly, objec-
tive) among the pool of patients, providers, and payers
whose interests are intimately involved in this miraculous
process.
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